ENZN Share Price

Open 0.44 Change Price %
High 0.45 1 Day 0.01 2.27
Low 0.44 1 Week 0.01 2.27
Close 0.45 1 Month 0.08 21.62
Volume 183483 1 Year -0.39 -46.43
52 Week High 0.88
52 Week Low 0.34
ENZN Important Levels
Resistance 2 0.46
Resistance 1 0.46
Pivot 0.45
Support 1 0.44
Support 2 0.44
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN)

ENZN Technical Analysis 3
As on 9th Dec 2016 ENZN Share Price closed @ 0.45 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.43 & Buy for SHORT-TERM with Stoploss of 0.39 we also expect STOCK to react on Following IMPORTANT LEVELS.
ENZN Target for December
1st Target up-side 0.56
2nd Target up-side 0.61
3rd Target up-side 0.66
1st Target down-side 0.4
2nd Target down-side 0.35
3rd Target down-side 0.3
ENZN Other Details
Segment EQ
Market Capital 296969696.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.enzon.com
ENZN Address
ENZN
20 Kingsbridge Road
Piscataway, NJ 08854
United States
Phone: 732-980-4500
Interactive Technical Analysis Chart Enzon Pharmaceuticals, Inc. ( ENZN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Enzon Pharmaceuticals, Inc.
ENZN Business Profile
Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company�s drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. The Company has four compounds in human clinical development, a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38, and mRNA antagonists Survivin and the Androgen Receptor (AR). In addition, it has mRNA antagonist targets in various stages of preclinical research. The Company receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its Customized Linker Technology-PEGINTRON. It is also using LNA technology to develop mRNA antagonists against oncology targets.